Fundraising FoxTheragenepharma
San Diego, US · Founded 2011 · 1 known investors
Find your way into Theragenepharma
Sign up to find every way you can get introduced to Theragenepharma
- Your email: who you already know at Theragenepharma, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Theragenepharma team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Theragene Pharmaceuticals develops immunotherapy and gene therapy treatments for cancer and cardiovascular diseases using AAV technology. The company operates in the US and Asia, pursuing partnerships for product development and licensing.
Founders & leadership
JB
Jon BerglinExecutive
Board
SD
Steven DavisBoard director
DC
Daniel CouryBoard director
CZ
Chaojie ZhangBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$548K disclosed across 2 rounds · 2014–2015
▶$200KraisedAug 2015 · 1 investors · BiotechnologyRule 506(b)
▶$200KraisedAug 2015 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Steven DavisDirector
- Daniel CouryDirector
- Chaojie ZhangDirector
- Jon BerglinExecutive Officer, Director
- Offering amount
- $30M
- Amount sold
- $200K
- Minimum investment
- $200K
- Proceeds to insiders
- $1.5M
- First sale
- Jul 2015
- Incorporated
- Corporation, California, 2011
- Federal exemptions
- 06b
▶$348KraisedMar 2014 · 7 investors · BiotechnologyRule 506(b)
▶$348KraisedMar 2014 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Chaojie ZhangDirector
- Steven DavisDirector
- Daniel CouryDirector
- Jon BerglinExecutive Officer, Director
- Offering amount
- $2M
- Amount sold
- $348K
- Minimum investment
- $5K
- First sale
- Feb 2014
- Incorporated
- Corporation, California, 2011
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
Allogene TherapeuticsAllogene Therapeutics develops allogeneic CAR T cell therapies (AlloCAR T) for blood cancers, solid tumors, and autoimmune diseases, using off-the-shelf manufactured cell products rather than patient-derived autologous approaches. The company aims to expand CAR T treatment access through scalable manufacturing, lower costs, and faster treatment delivery.
enGeneenGene is a genetic medicine company developing drug therapies across oncology, urology, and other therapeutic areas, with a focus on patient outcomes.
Companies working in the same space as Theragenepharma.
Frequently asked questions
- What does Theragenepharma do?
- Theragene Pharmaceuticals develops immunotherapy and gene therapy treatments for cancer and cardiovascular diseases using AAV technology. The company operates in the US and Asia, pursuing partnerships for product development and licensing.
- Who are Theragenepharma's investors?
- Theragenepharma's investors include Thynk Capital.
- How much funding has Theragenepharma raised?
- Theragenepharma has disclosed $548K raised across 2 rounds.
- Where is Theragenepharma headquartered?
- Theragenepharma is headquartered in San Diego, US.